Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Vanda To Pay Eli Lilly Up To $100 Million In Drug Development Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2012 | 01:50pm CET

Vanda Pharmaceuticals Inc. (>> Vanda Pharmaceuticals Inc.) agreed to pay Eli Lilly Co. (LLY) up to $100 million for the exclusive right to develop a drug that has shown some promise as a treatment for alcohol addiction.

Under its deal with Lilly, the biopharmaceutical company will pay a $1 million initial license fee and take responsibility for all development costs of the VLY-686 drug.

Lilly is also eligible to receive additional payments based upon certain milestones and royalties on sales. These milestones include $4 million for milestones achieved prior to a new drug application and up to $95 million for future regulatory approval and sales milestones.

Vanda, which focuses on treatments for central nervous system disorders, noted that prior research of VLY-686 has focused on its potential as a novel therapeutic for individuals struggling with dependence on alcohol.

"The licensing of VLY-686 is an important milestone for Vanda, as we continue to realize our vision of developing treatments to address unmet medical needs," said Chief Executive Mihael H. Polymeropoulos.

Vanda in February reported it swung to a loss in the fourth quarter as increased expenses outweighed higher revenue for the period.

Shares closed Friday at $4.49 and were inactive in premarket trade. The stock has slumped 42% over the past year.

-By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com

Stocks mentioned in the article : Vanda Pharmaceuticals Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
01:03p VANDA PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Financi..
12:46a VANDA PHARMACEUTICALS : Settles Fanapt® Patent Litigation with Apotex
11/22 VANDA PHARMACEUTICALS : Announces Participation at November 2016 Investor Confer..
11/17 VANDA PHARMACEUTICALS : Investigators from Vanda Pharmaceuticals Release New Dat..
11/14 VANDA PHARMACEUTICALS : Announces Participation at November 2016 Investor Confer..
11/08 VANDA PHARMACEUTICALS : Research Reports Coverage on Biotech Stocks -- Illumina,..
11/03 VANDA PHARMACEUTICALS : Settles Fanapt® Patent Litigation with Taro
11/03 VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
11/02 VANDA PHARMACEUTICALS : reports 3Q loss
11/02 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/28 VANDA : Valued Like A Plain Pharma Company, But Isn't One
11/19 Tracking John Paulson's Paulson & Company Portfolio - Q3 2016 Update
11/11 Healthcare ratings roundup - new coverage
11/04 BIOTECH FORUM DAILY DIGEST : DOJ Piles On Biopharma, Investment Case For Gilead ..
11/02 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q3 2016 Results - ..
Advertisement
Financials ($)
Sales 2016 148 M
EBIT 2016 -20,1 M
Net income 2016 -19,8 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 385,00
Capi. / Sales 2016 4,59x
Capi. / Sales 2017 3,66x
Capitalization 677 M
More Financials
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 22,5 $
Spread / Average Target 46%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Paolo Baroldi Chief Medical Officer & Senior Vice President
Howard H. Pien Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS ..65.41%677
AMGEN, INC.-13.02%105 034
GILEAD SCIENCES, INC.-28.08%95 884
CELGENE CORPORATION-5.93%87 334
REGENERON PHARMACEUTIC..-33.32%38 181
ACTELION LTD45.20%22 191
More Results